T cell immune tolerance is maintained in the periphery by a combination of extrinsic factors, including the action of regulatory T cells (Treg) and suppressive cytokines such as transforming growth factor β (TGFβ). TGFβ cytokines are positive and negative regulators of proliferation and differentiation in many cell lineages, and play a key role in maintaining peripheral T cell tolerance 1 . TGFβ signaling was shown to be essential to maintain peripheral T cell quiescence in vivo [2] [3] [4] [5] and to be a negative regulator of T cell proliferation in vitro 6 . Mice whose T cells are unresponsive to TGFβ signals either by expressing a dominant negative TGFβRII transgene 2, 4 , or through specific T cell deletion of the TGFβ receptor, Tgfbr1 3,5 die from fatal lymphoproliferative disease. In the absence of TGFβ signaling, peripheral CD4 + and CD8 + T cells become activated in a cellintrinsic fashion, most likely due to homeostatic expansion from the lymphopenic environment shortly after birth, and develop effector function and pathogenicity 7, 8 . Thus, TGFβ signals are particularly important for the regulation of the TCR-mediated, weak, self-ligand interactions that maintain peripheral T cell homeostasis.
TGFβ signaling is important also in restricting T cell responses to tumors 9, 10 . In the context of CD8 + T cells, TGFβ targets the transcription of key effector molecules and interferes with their ability to kill tumor cells 10 . These observations have led to the suggestion that targeting TGFβ sensitivity, for example, by inactivating the TGFβ receptor in T cells, could be beneficial in antitumor T cell therapy 11 .
There are several parallels between the induction of T cell autoimmunity and effective tumor immunosurveillance 12, 13 . T cells in autoimmune disease display functional characteristics that, in a tumor setting, may be beneficial. For example, autoreactive T cells respond effectively to poorly immunogenic antigens and are resistant to immune-regulatory mechanisms 2, 8 . Similarly, in order to mount effective anti-cancer responses, T cells need to overcome a strongly inhibitory tumor microenvironment, characterized by the presence of Tregs and high levels of inhibitory cytokines such as TGFβ. Indeed, TGFβ is expressed by a wide range of cancer cell types (https://portals. broadinstitute.org/ccle/home) as well as by tumor-infiltrating immune cells such as myeloid-derived suppressor cells 14 .
Genome-wide association studies have shown that the hematopoietic tyrosine phosphatase, PTPN22, has a commonly expressed variant, PTPN22 R620W , that is highly associated with predisposition to a number of autoimmune diseases 15, 16 . PTPN22 regulates Ag-specific T-and B-cell responses and some pattern recognition signaling pathways in myeloid cells that lead to production of type 1 interferons 15 . We showed previously that mouse Ptpn22 −/− T cells are partially resistant to wild-type Tregmediated suppression 17 and are more responsive to low-affinity antigens 18 . Given the critical dual role of TGFβ in limiting autoimmune and anti-tumor responses, we investigated the impact of PTPN22 deficiency on the responses of CD8 + T cells to this key inhibitory cytokine. Furthermore, we sought to test the hypothesis that PTPN22 acts as a brake to limit the effectiveness of anti-tumor T cell responses. We show that Ptpn22 −/− CD8 T cells are considerably more resistant to the suppressive effects of TGFβ than WT T cells. Concentrations of TGFβ that suppress proliferation and differentiation of effector cytokines in WT T cells show little inhibition of these processes in Ptpn22 −/− CD8 T cells. Upon stimulation with both weak and strong agonists peptides Ptpn22 −/− CD8 T cells produce more IL-2 than WT T cells and IL-2 interferes with the suppressive effect of TGFβ. Consequently upon adoptive transfer, Ptpn22 −/− CD8 T cells are better able than WT CD8 T cells to control the growth of established tumors that secrete TGFβ. Importantly, the superior anti-tumor capacity of Ptpn22 −/− CD8 + T cells is observed in response to both strong and weak antigens, the latter being a common trait of tumor-associated antigens, which can otherwise limit robust anti-tumor immune responses. These results suggest that targeting genes associated with susceptibility to autoimmunity may be a viable strategy to improve the efficacy of adoptive T cell immunotherapy.
Results
Ptpn22 −/− T cells resist TGFβ-mediated suppression. TGF-β was shown previously to suppress low-affinity T cell responses more effectively than high-affinity responses 8 and we showed a similar role for PTPN22 in limiting CD8 + T cell responses 18 . Using the OVA-specific TCR transgenic mouse, OT-1 on a Rag-1 −/− background (hereafter called OT-1 T cells), for which a number of peptides have been characterized, which span a range of affinities 19 , we examined the sensitivity of control and Ptpn22 −/− OT-1 T cells to inhibition by TGFβ in vitro.
As reported previously 8 , TGFβ markedly inhibited antigeninduced proliferation of OT-1 TCR transgenic T cells in a dosedependent manner (Fig. 1a-c) . This suppression occurred following stimulation both with strong agonist, SIINFEKL (N4) peptide and with weak agonist, SIITFEKL (T4) peptide. Enhanced proliferation of Ptpn22 −/− OT-1 T cells compared to control OT-1 cells was particularly apparent in response to weak agonist peptide, T4, in the absence of TGFβ (Fig. 1a-c) , as we reported previously 18 . Significantly, both N4-and T4-induced proliferation of Ptpn22 −/− OT-1 T cells were extremely refractory to TGFβ inhibition (Fig. 1a-c) compared to control OT-1 T cells. In response to N4 peptide, no inhibition of Ptpn22 −/− OT-1 T cell proliferation was seen at doses of up to 5 ng/ml TGFβ, while in response to T4 peptide, Ptpn22 −/− OT-1 T cells required~10-fold higher concentrations of TGFβ than control OT-1 T cells to show equivalent suppression of proliferation.
The mechanism of TGFβ-mediated suppression of T cell responses is not well understood. PTPN22 is known to target signaling molecules immediately downstream of the TCR, such as Lck and ZAP70, so it was unclear why Ptpn22 −/− T cells would be more resistant than control T cells to TGFβ-mediated suppression. We asked at what point TGFβ suppression acted to inhibit control OT-1 T cells. Time-course analysis demonstrated that TGFβ inhibition of OT-1 T cell proliferation was apparent at day 3 ( Fig. 1d) , but in order to achieve this, TGFβ needed to be present from the start of culture. Delaying addition of TGFβ by 2 days failed to limit antigen-induced proliferation (Fig. 1e) . Similarly, TGFβ-mediated inhibition of OT-1 T cell proliferation could be alleviated by an inhibitor to the TGFβ receptor, but only when added from the beginning of culture (Fig. 1f) .
These data show that TGFβ acted early in T cell activation, as by 48 h after stimulation cells were resistant to the antiproliferative effects of TGFβ. Accordingly, we analyzed activation marker and transcription factor expression at 24 h following stimulation of OT-1 T cells. In control OT-1 T cells, TGFβ limited the extent of weak agonist T4-induced upregulation of the IL-2 receptor-α chain (CD25), and key transcription factors Myc and IRF4, but less so Tbet, whereas Ptpn22 −/− OT-1 T cells were refractory to these inhibitory effects of TGFβ (Fig. 2a, b) . These data indicate that loss of PTPN22 counteracted TGFβ inhibition during the early phase of TCR engagement.
Ptpn22 −/− CD8 + T cells are superior at tumor clearance. The resistance of Ptpn22 −/− T cells to TGFβ-mediated suppression in vitro led us to ask whether these CD8 + T cells would be more effective for adoptive cell therapy against TGFβ-secreting tumors in vivo. First, we evaluated the ability of control and Ptpn22 −/− OT-1 T cells to reject EL4 lymphoma cells (EL4-OVA) expressing high-affinity N4 peptide as a tumor-specific antigen. EL4-OVA tumors were established subcutaneously for 5d before transfer of small numbers (5 × 10 4 /mouse) of either control or Ptpn22 −/− naive OT-1 T cells. Tumor size was monitored for a further 7d after which mice were killed to prevent control animals exceeding permitted tumor volumes, and wet tumor mass measured. Strikingly, Ptpn22 −/− OT-1 T cells were significantly superior to control cells in controlling growth of subcutaneous EL4-OVA tumors (*p < 0.05 using two-way ANOVA with Tukey's post test) (Fig. 3a) . In particular, very few animals receiving Ptpn22 −/− OT-1 T cells showed evidence of tumor mass over the time course following transfer, whereas a number of those receiving control OT-1 T cells showed ongoing tumor growth followed by regression toward the end of the experiment.
TGFβ is secreted by EL4 cells, so we asked to what extent TGFβ was preventing tumor rejection by OT-1 T cells 2, [20] [21] [22] . Subcutaneous tumors were established as before, but with an EL4-OVA cell line engineered to express a soluble form of the TGFβRII (EL4-OVA STβRII) 10 . Adoptively transferred control OT-1 T cells were better able to reduce tumor growth when TGFβ was blocked, as shown previously 10 , while Ptpn22 −/− OT-1 T cells effected complete rejection of EL4-OVA STβRII cells (20/20 mice) (Fig. 3b) . These data illustrate that while, not completely immune to TGFβ inhibition, Ptpn22 −/− T cells are inherently superior in managing growth of TGFβ-secreting tumors.
Key to control of tumor mass is the ability of CD8 + T cells to kill tumor targets. TGFβ acts to inhibit the expression of several cytolytic gene products, thus hindering CD8 T cell cytotoxicity 10 . To better mimic responses to weak tumor antigens, we used ID8 murine ovarian carcinoma cells 23 that as a tumor-specific antigen expressed the weak agonist peptide, T4, which is~70-fold less potent in stimulating OT-1 T cells than N4 peptide 24 , and is of equivalent affinity to self-peptides that select the thymic repertoire 19 . We cultured ID8-T4 cells with control and Ptpn22 −/− OT-1 T cells in vitro and monitored production of granzyme B (GzB) and IFNγ. Remarkably, while GzB was detectable in less than 10% of control cells,~70% of Ptpn22 −/− T cells were positive for GzB and a substantial proportion of the latter also expressed IFNγ in response to ID8-T4 cells alone. Blockade of TGFβ signaling by addition of a TGFβ-receptor inhibitor relieved the suppression of control T cells so that now~40% expressed granzyme B while >90% of Ptpn22 −/− cells became GzB + (Fig. 3c ) . We then compared the ability of control and Ptpn22 −/− OT-1 CD8 + TCR transgenic T cells to respond to tumors expressing low-affinity TSA in vivo. ID8-T4 tumors were established in the peritoneum of recipient B6 (CD45.1/CD45.2F 1 ) mice for 28d before transfer of an equal mixture of control CD45.1 + and Ptpn22 −/− CD45.2 + OT-1 T cells. Three days later, we found significantly enhanced proliferation of Ptpn22 −/− OT-1 T cells compared to control cells in individual mice (Fig. 3d , **p < 0.01 using two-way ANOVA with Tukey's post test) showing that Ptpn22 −/− T cells indeed proliferate more in response to the weak T4 antigen expressed by the tumor.
In order to non-invasively assess ID8 tumor growth in vivo, we transduced ID8-T4 cells with lentivirus-expressing Firefly luciferase (Fluc), enabling us to monitor bioluminescence as a correlate of tumor mass. Tumors were established in the peritoneum of B6 mice prior to adoptive transfer of control or Ptpn22 −/− OT-1 T cells, that were first activated in vitro. Tumor bioluminescence was analyzed 14d post T cell transfer. While control OT-1 T cells reduced tumor mass in a number of recipient mice, this effect did not reach statistical significance (Fig. 3e) . By contrast, adoptive cell transfer of Ptpn22 −/− OT-1 cells resulted in a significant decrease in luminescence signal, and in the majority of mice, a complete rejection of tumor load (Fig. 3e , *p < 0.05 using two-way ANOVA with Tukey's post test).
Taken together, our data using EL4 lymphoma and ID8 ovarian carcinoma models indicate that Ptpn22 −/− T cells generate a more effective anti-tumor responses to both highand low-affinity TSA. This effect most likely stems from a combination of the enhanced TCR responsiveness and proliferation of cells lacking PTPN22 to both high-and low-affinity TSA and their reduced susceptibility to inhibitory cytokines such as TGFβ, permitting differentiation and expression of effector cytokines and the cytolytic machinery.
Canonical TGFβR signaling is unaffected by loss of PTPN22. We next assessed the mechanisms underlying the ability of Ptpn22 −/− T cells to overcome TGFβ-mediated suppression. Surface TGFβRII expression (Fig. 4a) and canonical TGFβRII signaling, judged by TGFβ-induced phospho-SMAD (Fig. 4b) , were identical in control and Ptpn22 −/− OT-1 T cells. Furthermore, in both genotypes, there was SMAD-dependent inhibition of granzyme B expression 20 and upregulation of CD44 expression by high-dose TGFβ (Fig. 4c) . Recent analyses have shown that expression of the transcription factor FoxP1 is essential for TGFβ-mediated suppression of anti-tumor T cells 25 , however, levels of FoxP1 expression by control and Ptpn22 −/− T cells were comparable under basal and activated conditions (Fig. 4d) .
In order to determine whether TGFβ directly affects PTPN22 function, we analyzed the phosphorylation of well-defined PTPN22 substrates ZAP70 and TCRζ 26 following TCR stimulation of control OT-1 T cells in the presence or absence of TGFβ. Importantly, TGFβ did not impair basal or TCR-stimulated levels of Zap70 Y493, TCRζ Y83, or ERK MAPKinase phosphoryation (Fig. 4e) . Previous data have shown that PTPN22 associates with Csk, which may be important for its function in T cells 27 . However, co-immunoprecipitation of PTPN22 with Csk was unaffected by culture of OT-1 T cells with TGFβ (Fig. 4f) . Together, these data show that PTPN22 does not impact directly upon canonical SMAD-dependent TGFβ receptor signaling IL-2 protects against TGFβ-mediated suppression. Our data suggested that indirect mechanisms were likely to underlie the ability of Ptpn22 −/− T cells to resist TGFβ inhibition. Serendipitously, we noted that when control and Ptpn22 −/− OT-1 T cells were activated with T4 peptide as a 1:1 mix in the same culture wells, the inhibitory effect of TGFβ on control T cell proliferation was abrogated (Fig. 5a ). These data suggested that Ptpn22 −/− T cells secreted or expressed a factor that "rescued" control cells from the effects of TGFβ in a co-culture system. Culture of control and Ptpn22 −/− T cells in transwells also abrogated the inhibitory effect of TGFβ on control T cell proliferation, indicating that a soluble factor was responsible for the protective effect (Fig. 5a, b) . TGFβ was shown to limit T cell IL-2 production 20,28,29 and a protective effect of IL-15 and other common gamma chain cytokines on TGFβ suppression has been reported 7, 30 . We found that, compared with control cells, Ptpn22 −/− OT-1 T cells secreted significantly greater quantities of IL-2 in response to both strong N4 and weak T4 agonist peptides (Fig. 5c , ***p < 0.001 and ****p < 0.0001 using two-way ANOVA with Tukey's post test). Importantly, TGFβ treatment almost completely blocked control but not Ptpn22 −/− OT-1 T cell IL-2 production (Fig. 5c) . Two distinct approaches confirmed the importance of elevated TCR-induced IL-2 production for the ability of Ptpn22 −/− T cells to resist TGFβ-mediated inhibition. First, canonical IL-2-dependent signaling pathways were blocked using the inhibitor tofacitinib, which inhibits Jak3 in addition to other members of the Jak kinase family. Tofacitinib markedly reduced the ability of Ptpn22 −/− OT-1 T cells to withstand TGFβ-mediated inhibition, indicating that IL-2 cytokine receptor signaling was important for the resistance of Ptpn22 −/− cells to TGFβ (Fig. 5d) . Second, the addition of recombinant IL-2 to T cell cultures prevented the inhibitory effects of TGFβ on OT-1 T cell proliferation when added at either d0 or on d2 (Fig. 5e) . Recovery of proliferation was dose dependent (Fig. 5f ) confirming that insufficiency of IL-2 production in the presence of TGFβ accounted for the inhibition of OT-1 T cell proliferation. Together, these data strongly suggest that elevated IL-2 production in response to TCR triggering enables Ptpn22 −/− T cells to overcome the inhibitory effects of TGFβ.
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Previous studies have suggested that TGFβ interferes with TCR-induced Ca 2+ signaling and subsequent NFAT activation, thereby limiting T cell activation and IL-2 production 31 . We have shown previously that Ca 2+ fluxes in naive T cells were not influenced by the absence of Ptpn22 17 . However, in vitro measurement of Ca 2+ flux in primary naive T cells by FACS requires very acute and strong stimulation, e.g., in the OT-1 model by using multivalent peptide:MHC complexes containing strong agonist peptide N4 32 . Under these stimulation conditions, we saw no reduction of Ca 2+ signals in control OT-1 T cells in the presence of TGFβ (Supplementary Fig. 1 ). However, we reasoned that looking more downstream, e.g., at NFAT nuclear translocation might reveal some differences. Indeed, we observed significant inhibition of NFAT nuclear translocation in the presence of TGFβ when control OT-1 T cells were stimulated with T4 peptide (Fig. 5g , ****p < 0.0001 using Student's t test). In contrast, T4-induced NFATc1 nuclear translocation in stimulated Ptpn22 −/− CD8 T cells was remarkably resistant to suppression by TGFβ (Fig. 5g) . These data corroborate the finding that TGFβ suppresses control CD8 T cell proliferation by interfering with IL-2 production through inhibition of NFAT activation, and indicate that in the absence of PTPN22, this inhibitory pathway is circumvented.
Discussion
The ability of T cells to integrate and respond appropriately to a complex network of signals triggered by antigen receptor engagement, cytokines, chemokines, and other environmental signals is critical to the outcome of immune responses. Furthermore, in order to maintain tolerance, cell-intrinsic inhibitory mechanisms and the action of suppressive cytokines, including TGFβ prevent T cell activation by low-affinity self-antigens. In the current work, we found that altering the sensitivity of TCR signaling, by deletion of the autoimmune-associated phosphatase PTPN22, further impacted upon the sensitivity of CD8 + T cells to the suppressive effects of TGFβ. Our results describing the consequent imbalance in positive and negative signaling have important implications for our understanding of the mechanisms regulating autoimmune T cells and may also have practical applications in tumor therapy. In this regard, we showed that the combination of enhanced TCR sensitivity and subsequent resistance to TGFβ inhibition enabled Ptpn22 −/− T cells to have potent anti-tumor effector function in vivo.
A key mechanism underlying resistance to TGFβ suppression was the ability of Ptpn22 −/− T cells to produce IL-2 more abundantly than control T cells. Other studies have shown that Ptpn22 −/− CD4 + T cells make more cytokines, including IL-2, than WT T cells 33, 34 and we show that is true for Ptpn22 −/− CD8 + cells also. Previous data indicated that Smad3-dependent inhibition of Il2 transcription and protein expression was key to TGFβ-induced suppression of TCR-induced T cell proliferation 35 . Consistent with this, in our studies, suppression of peptideinduced control OT-1 T cell proliferation could be reversed by addition of recombinant IL-2 to cultures. It is worthy of note that PTPN22 does not directly regulate IL-2 33 or TGFβ receptor signaling pathways. Therefore, it is likely that the ability of Ptpn22 −/− T cells to withstand TGFβ-induced suppression is a result of quantitative effects of elevated IL-2 production rather than qualitative effects on IL-2R or TGFβR signaling. In addition, our data highlight the complexity of the interplay between IL-2 and TGFβ signaling on T cell responses. In this regard, IL-2 abrogates the pro-inflammatory effects of TGFβ on CD4 + Th17 differentiation and instead favors inducible Treg expansion 36 . By contrast, our data show that elevated IL-2 production by CD8 + T cells abrogates suppressive effects of TGFβ and instead favors a proinflammatory response. Thus, the effects of these two cytokines in vivo are likely to be highly context dependent.
The mechanisms by which TGFβ inhibits TCR signaling and T cell function are not fully understood. An early report suggested that, in CD4 + T cells, TGFβ signals interfere with very early TCRinduced Tek and ERK kinase activation and NFAT nuclear translocation 31 . Our data support this view as we saw clear inhibition of NFAT translocation in control cells incubated with TGFβ, whereas Ptpn22 −/− T cells were resistant to this inhibiiton. Analysis of more upstream pathways did not reveal more specifically how TGFβ inhibition intersects TCR signaling, as we saw no change in TCRζ, Zap70, or MAPK signaling in WT T cells stimulated in the presence or absence of TGFβ. However, these assays utilize strong stimulation of the TCR over very short time frames and may therefore lack the sensitivity to observe TGFβ inhibition. More recently, TGFβ-mediated T cell suppression has been linked to effects on the mTOR pathway 37 . In those studies, suppressive effects of TGFβ on mTOR signaling were assessed following 36 h (or more) of T cell stimulation, time points at which autocrine IL-2 signals contribute to mTOR activation 38 . Therefore, it is possible that TGFβ inhibition of mTOR signals at these later time points might, at least in part, be explained by reduced IL-2 secretion. In NK cells, TGFβ also suppresses mTOR activation with potent downstream effects on cellular metabolism 39 . Given the importance of shifts in cellular metabolism in the generation and differentiation of effector T cells, it will be interesting to determine whether TGFβ also impedes these processes in T cells. A recent study indicated that FoxP1 expression was required for TGFβ-mediated inhibition of anti-tumor CD8 + T cells 25 . However, our data showed that Ptpn22 −/− and control OT-1 T cells expressed equivalent levels of FoxP1. Therefore, it is likely that FoxP1 expression is necessary but not sufficient to mediate TGFβ suppression.
Our experiments provide new insight into the mechanisms by which PTPN22 dampens T cell activation. Loss of PTPN22 function increases the chance of T cells responding to weak, selfantigens and this enhanced TCR sensitivity is compounded by a knock-on effect on the inhibitory TGFβ pathway. While these effects are likely to be detrimental in the context of autoimmune disease, they also raise the possibility that GWAS-identified, autoimmune susceptibility loci can be manipulated to improve the intrinsic efficacy of adoptive cell therapy (ACT) for cancer. In this regard, we showed that Ptpn22 −/− T cells were superior to control cells in responding to both high-and low-affinity TSA and in mediating tumor rejection in vivo, suggesting that targeting PTPN22 may be a viable approach in T cell immunotherapies. We reason that in future studies, by restricting loss of PTPN22 to tumor-specific T cells, undesirable autoimmunity will be minimized. Despite the recent success of chimeric antigen receptors 40 , a major advantage of retaining TCR expression for ACT is that many TSAs are intracellular proteins that are only presented in the context of MHC. However, TSAs are frequently too weak to stimulate effective T cell responses, but by manipulating the intracellular signaling machinery, we show that it is possible to harness traits that are undesirable in autoreactive T cells, such as reactivity to weak antigens and resistance to suppressive cytokines, for the benefit of anti-tumor responses.
Methods
Mice. Rag-1 −/− OT-I CD45.1 +/+ 40 , Ptpn22 −/− Rag-1 −/− OT-I CD45.2 +/+ 18 and CD45.1 +/− CD45.2 +/− mouse strains were bred and maintained under specific and opportunistic pathogen-free conditions at the Universities of Edinburgh and Leeds. Age-matched (6-12 weeks) and sex-matched mice were used in all experiments. Animal procedures were approved under a UK Home Office project license and were performed in compliance with the ethical guidelines of the Universities of Edinburgh and Leeds.
